Applying HIV Advances in PracticeWhat the Pharmacist Needs to Know
Academy of Managed Care Pharmacy.
Chaudhary K, Patel MM, Mehta PJ. Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181.
McGowan JP, Fine SM, Vail RM, et al. Baltimore (MD): Johns Hopkins University; 2022.
Gupta SK, Sims J, Brinson C, et al. Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.
Johnson K, Sawkin MT. Drugs Context. 2022;11:2021-9-2.
Little J, Ortega M, Powell M, Hamm M. Am J Health Syst Pharm. 2019;76(4):251-253.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, Hung CC, Brinson C, et al. Lancet. 2018;391(10123):839-849.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
Vachiat A, McCutcheon K, Tsabedze N, et al. J Am Coll Cardiol. 2017;69(1):73-82.
Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.
van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020;71(8):1920-1929.
How to Counsel Your HIV Patients as Treatment Choices Expand
What the Pharmacist Needs to Know to Optimize ART Regimens
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice